Prevention of Novel Coronavirus Disease by Hydroxychloroquine in cancer patients.

Effect of Hydroxychloroquine on Novel Coronavirus Disease (COVID-19) prevention in cancer patients under treatment

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200405046958N1

Enrollment

Registered

2020-04-14

Start date

2020-04-13

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: COVID-19 disease. Condition 2: Acute myeloid leukemia. Condition 3: Acute lymphoblastic leukemia. Condition 4: Breast cancer. Condition 5: Colon cancer. Condition 6: Diffuse large B cell lymphoma. Coronavirus infection, unspecified Acute myeloblastic leukemia Acute lymphoblastic leukemia [ALL] Malignant neoplasm of breast Malignant neoplasm of colon Diffuse large B-cell lymphoma

Interventions

Intervention 1: Intervention arm: Patients in this group receive 200 mg of hydroxychloroquine tablets (manufactured by Amin Pharmaceutical Company, Isfahan) every other day for 2 months. At the same t

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with curable Acute Lymphoblastic Leukemia Patients with curable Acute Myeloblastic Leukemia Patients with curable high-grade non-Hodgkin Lymphoma Patients with curable Breast cancer Patients with curable Colon cancer Age higher than 15 years

Exclusion criteria

Exclusion criteria: Known sensitivity to Hydroxychloroquine Weight lower than 35 kilograms History of retinopathy History of any cardiac disease Acute respiratory tract infection in the last 2 month Having novel Coronavirus in the first two weeks of entering the trial Diabetes Mellitus Immuno-suppressive disease other than cancer Chronic pulmonary disease Taking immuno-suppressive drugs other than cancer chemotherapy

Design outcomes

Primary

Measure	Time frame
COVID-19 incidence rate in cancer patients under treatment. Timepoint: Patients are examined and investigated if they become symptomatic during the 2 months of study. Method of measurement: First, a history and physical examination are performed for the symptoms of COVID-19, and if the test is positive, a computerized tomography scan of the lungs and a nucleic acid amplification test for the SARS-CoV-2 virus.	—

Measure

Time frame

COVID-19 incidence rate in cancer patients under treatment. Timepoint: Patients are examined and investigated if they become symptomatic during the 2 months of study. Method of measurement: First, a history and physical examination are performed for the symptoms of COVID-19, and if the test is positive, a computerized tomography scan of the lungs and a nucleic acid amplification test for the SARS-CoV-2 virus.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Moeini Nodeh

Mashhad University of Medical Sciences

moeininm@mums.ac.ir+98 51 3801 2742

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 26, 2026